103 related articles for article (PubMed ID: 23803017)
21. Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator.
Okazaki M; Kishida S; Hinoi T; Hasegawa T; Tamada M; Kataoka T; Kikuchi A
Oncogene; 1997 Feb; 14(5):515-21. PubMed ID: 9053849
[TBL] [Abstract][Full Text] [Related]
22. Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap.
Spaargaren M; Bischoff JR
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12609-13. PubMed ID: 7809086
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
[TBL] [Abstract][Full Text] [Related]
24. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
[TBL] [Abstract][Full Text] [Related]
25. Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.
Kent OA; Sandi MJ; Rottapel R
Small GTPases; 2019 Nov; 10(6):441-448. PubMed ID: 28656876
[TBL] [Abstract][Full Text] [Related]
26. Regulation of Ras signaling specificity by protein kinase C.
Rusanescu G; Gotoh T; Tian X; Feig LA
Mol Cell Biol; 2001 Apr; 21(8):2650-8. PubMed ID: 11283245
[TBL] [Abstract][Full Text] [Related]
27. RalGDS is required for tumor formation in a model of skin carcinogenesis.
González-García A; Pritchard CA; Paterson HF; Mavria G; Stamp G; Marshall CJ
Cancer Cell; 2005 Mar; 7(3):219-26. PubMed ID: 15766660
[TBL] [Abstract][Full Text] [Related]
28. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
Mirzoeva OK; Collisson EA; Schaefer PM; Hann B; Hom YK; Ko AH; Korn WM
Mol Cancer Ther; 2013 Oct; 12(10):2213-25. PubMed ID: 23918833
[TBL] [Abstract][Full Text] [Related]
29. Activation of RalA is critical for Ras-induced tumorigenesis of human cells.
Lim KH; Baines AT; Fiordalisi JJ; Shipitsin M; Feig LA; Cox AD; Der CJ; Counter CM
Cancer Cell; 2005 Jun; 7(6):533-45. PubMed ID: 15950903
[TBL] [Abstract][Full Text] [Related]
30. Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease.
Turrini O; Gilabert M; Ewald J; Moutardier V; Delpero JR; Iovanna JL
J Visc Surg; 2017 Oct; 154(5):329-333. PubMed ID: 28844705
[TBL] [Abstract][Full Text] [Related]
31. Resection of multiple invasive pancreatic ductal adenocarcinomas: A diagnostic dilemma distinguishing multicentric carcinogenesis from intrapancreatic metastasis.
Ohike N; Norose T; Takano Y; Niiya F; Nagahama M; Matsuo K; Tanaka K; Furukawa T
Pathol Int; 2020 Aug; 70(8):588-590. PubMed ID: 32515154
[No Abstract] [Full Text] [Related]
32. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
33. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
34. [Kras oncogene and pancreatic cancer: thirty years after].
Bournet B; Dufresne M; Selves J; Torrisani J; Cordelier P; Buscail L
Med Sci (Paris); 2013 Nov; 29(11):991-7. PubMed ID: 24280502
[TBL] [Abstract][Full Text] [Related]
35. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
36. Role of RAS signaling in ovarian cancer.
Therachiyil L; Anand A; Azmi A; Bhat A; Korashy HM; Uddin S
F1000Res; 2022; 11():1253. PubMed ID: 36451660
[TBL] [Abstract][Full Text] [Related]
37. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
[TBL] [Abstract][Full Text] [Related]
38. The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways.
Hernandez-Muñoz I; Malumbres M; Leonardi P; Pellicer A
Oncogene; 2000 May; 19(23):2745-57. PubMed ID: 10851075
[TBL] [Abstract][Full Text] [Related]
39. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.
Ramírez de Molina A; Penalva V; Lucas L; Lacal JC
Oncogene; 2002 Jan; 21(6):937-46. PubMed ID: 11840339
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of CD40-induced N-Ras activation reduces leishmania major infection.
Chakraborty S; Srivastava A; Jha MK; Nair A; Pandey SP; Srivastava N; Kumari S; Singh S; Krishnasastry MV; Saha B
J Immunol; 2015 Apr; 194(8):3852-60. PubMed ID: 25786685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
